Anadys Pharmaceuticals, Inc. said that 72% of hepatitis C patients receiving its experimental drug in combination with the current standard of care or SOC achieved undetectable levels of virus at week eight compared to 38% of patients receiving placebo plus SOC.
The results were derived from an ongoing mid-stage study, in which the patients received either the drug candidate – ANA598 400 mg twice daily dose plus SOC or ANA598 200 mg twice daily dose plus SOC or placebo plus SOC.
ANA598 is wholly owned by Anadys, which has completed three Phase I clinical studies of the drug demonstrating potent antiviral activity and good tolerability.
The preliminary analysis of results through eight weeks also showed that ANA598 400 mg twice daily dose plus SOC was well tolerated, with an adverse event profile comparable to SOC alone, the company noted, adding that at 200 mg twice daily dose of the drug, no patient experienced viral breakthrough, which is an increase in viral load while on antiviral treatment.
The results were derived from an ongoing mid-stage study, in which the patients received either the drug candidate – ANA598 400 mg twice daily dose plus SOC or ANA598 200 mg twice daily dose plus SOC or placebo plus SOC.
ANA598 is wholly owned by Anadys, which has completed three Phase I clinical studies of the drug demonstrating potent antiviral activity and good tolerability.
The preliminary analysis of results through eight weeks also showed that ANA598 400 mg twice daily dose plus SOC was well tolerated, with an adverse event profile comparable to SOC alone, the company noted, adding that at 200 mg twice daily dose of the drug, no patient experienced viral breakthrough, which is an increase in viral load while on antiviral treatment.
